Christensen J E, Varnek L, Gregersen G
Acta Neurol Scand. 1985 Feb;71(2):164-7. doi: 10.1111/j.1600-0404.1985.tb03182.x.
37 patients with diabetic neuropathy were randomized into 2 equal groups and given daily doses of 200 mg or 50 mg of Sorbinil - a potent aldose-reductase inhibitor - in a double-blind 4-week period between 2 periods on placebo. The purpose was to assess the role of the drug on various neurophysiological parameters and its clinical effect. No difference was shown either in the placebo periods compared to Sorbinil treatment or between the 2 groups on the neurophysiological parameters but there was a statistically significant effect on overall subjective well-being. The drug had no side-effects in the present study.
37例糖尿病性神经病变患者被随机分为两组，每组人数相等。在两个安慰剂治疗阶段之间，进行为期4周的双盲试验，分别给予每日200毫克或50毫克的索比尼尔（一种有效的醛糖还原酶抑制剂）。目的是评估该药物对各种神经生理学参数的作用及其临床效果。在安慰剂阶段与索比尼尔治疗阶段相比，以及两组在神经生理学参数方面均未显示出差异，但对总体主观幸福感有统计学意义的影响。在本研究中，该药物没有副作用。
